Back to top
more

Aytu BioPharma (AYTU)

(Delayed Data from NSDQ)

$3.17 USD

3.17
21,544

-0.06 (-1.86%)

Updated Jun 4, 2024 03:56 PM ET

After-Market: $3.14 -0.03 (-0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AYTU

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Aytu BioPharma Inc falls in the month of June.

All items in Millions except Per Share data.

6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Assets          
Cash & Equivalents 23 19 50 48 11
Receivables 29 22 28 5 2
Notes Receivable 0 0 0 0 0
Inventories 12 11 16 10 1
Other Current Assets 9 8 11 11 1
Total Current Assets 73 60 105 75 15
Net Property & Equipment 2 3 5 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 59 71 151 77 19
Deposits & Other Assets 1 1 0 0 0
Total Assets 136 138 266 153 35
Liabilities & Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 13 11 19 12 2
Current Portion Long-Term Debt 2 4 28 3 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 47 44 57 11 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 7 5 4 2 1
Total Current Liabilities 69 64 109 28 5
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 15 14 7 11 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 13 13 10 18 22
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 97 92 128 58 28
Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 343 335 316 215 113
Retained Earnings -304 -288 -178 -120 -106
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 39 46 138 95 7
Total Liabilities & Shareholder's Equity 136 138 266 153 35
Total Common Equity 39 46 138 95 7
Shares Outstanding 3.70 1.90 1.20 0.60 0.00
Book Value Per Share 10.64 24.26 114.64 158.37 7.09

Fiscal Year End for Aytu BioPharma Inc falls in the month of June.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 20 20 20 23 19
Receivables 30 29 30 29 34
Notes Receivable 0 0 0 0 0
Inventories 13 13 13 12 14
Other Current Assets 8 9 8 9 12
Total Current Assets 71 71 71 73 78
Net Property & Equipment 1 1 2 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 54 56 57 59 63
Deposits & Other Assets 1 1 1 1 1
Total Assets 129 131 133 136 147
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 10 10 14 13 15
Current Portion Long-Term Debt 17 1 1 2 14
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 44 43 41 47 50
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 9 9 7 7
Total Current Liabilities 84 64 65 69 85
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 15 15 15 11
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 14 20 13 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 98 98 101 97 106
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 346 345 344 343 343
Retained Earnings -315 -312 -312 -304 -302
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 31 33 32 39 41
Total Liabilities & Shareholder's Equity 129 131 133 136 147
Total Common Equity 31 33 32 39 41
Shares Outstanding 5.50 5.50 5.50 3.70 3.70
Book Value Per Share 5.60 5.97 5.85 10.64 11.06